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ABSTRACT
CHARACTERIZING THE ROLES OF NEUTRAL CERAMIDASE IN CISPLATININDUCED KIDNEY INJURY
Sophia M. Sears
August 15, 2019
Cisplatin is a commonly used chemotherapeutic agent with a dose-limiting
nephrotoxicity. 30% of patients given cisplatin develop acute kidney injury (AKI).
AKI increases risk of chronic kidney disease (CKD) development and mortality.
Patients that don’t develop clinical AKI are still at risk for long term declines in
renal function. Currently, there are no FDA approved agents to treat or prevent
cisplatin-induced kidney injury (CDDP-KI). In this study, we demonstrated that
neutral ceramidase (nCDase) knockout provides protection from AKI in the highdose model of CDDP-KI. However, in the repeated low dose cisplatin (RLDC)
model of injury and we found nCDase knockout does not prevent development of
CKD. We also observed that nCDase knockout reduces induction of ER stress in
the single high-dose model but not in the RLDC model. This study suggests there
are unique mechanisms of RLDC induced kidney injury which may have hindered
development of nephroprotective agents.
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INTRODUCTION
ACUTE KIDNEY INJURY
Epidemiology and Defining AKI
Acute kidney injury (AKI) is defined as a rapid decrease in renal function
characterized by a decrease in glomerular filtration rate (GFR) and an increase in
retained waste products.[1] It is one of the most common life-threatening
conditions associated with hospital admissions. Since 2002, it has been
estimated that 25% of patients admitted to the hospital develop AKI. [2, 3]
Development of AKI increases risk of mortality 5.5-6.5 fold compared to similarly
ill patients who do not develop AKI.[4]
As our population ages, incidence of AKI is increasing. Age alone
increases the likelihood of AKI development, but the increase in complications
such as hypertension, cardiovascular disease, and chronic kidney disease also
increase vulnerability to AKI. Therapeutic interventions such as surgery and
chemotherapy put patients at risk for AKI as well. All of these factors have
contributed to the steadily increasing incidence of AKI, particularly among elderly
hospitalized patients.[2] Financially, the rise in AKI cases is problematic. In 2005,
the financial burden of AKI was estimated to be $10 billion in additional cost to
the health care system in the United States.[4]
The exact prevalence of AKI has been difficult to monitor due to its broad
definition and variable methods of measuring renal function. An important
1

function of the kidney is to filter out nitrogenous waste products from the blood to
be excreted in the urine. A decline in GFR can therefore be observed by an
increase in circulating nitrogenous compounds. Serum creatinine and blood urea
nitrogen (BUN) are two products that can be measured to estimate GFR.
Increased concentrations of these products in the blood corresponds to a
decreased renal clearance. Therefore, serial measurements of serum creatinine
and BUN can provide an idea of declining kidney function.[4] Until recently, there
had not been set quantitative standards of kidney function that described an AKI
diagnosis.
In order to provide more clarity, the RIFLE classification
(Risk/Injury/Failure/Loss/End-stage renal disease) and AKIN classification (Acute
Kidney Injury Network) were published providing measurable criteria to define
stages of kidney injury based on measurements of serum creatinine and urine
output.[2] The RIFLE scale classifies kidney injury cases by severity into
categories of risk, injury, or failure. It further classifies outcomes of kidney injury
as either loss of function or end stage renal disease. By RIFLE definitions, AKI
corresponds to a doubling in patient serum creatinine from baseline and a 50%
reduction in GFR with urine output dropping below 0.5 ml/kg/hr for 12 hours.
Renal function must decline to these levels in 1 to 7 days and remain below
these standards for at least 12 hours.[5, 6]
In 2007, the AKIN classification was published to expand on the RIFLE
classification. AKIN standards do not require estimation of baseline serum
creatinine and considers diagnosis of AKI only after achieving adequate
2

hydration and excluding urinary obstruction. AKI is diagnosed as stage 1, 2, or 3
based on the increase of serum creatinine within 48 hours, rather than from an
estimated baseline. Stage 1, 2, and 3 on the AKIN scale corresponds to the risk,
injury, and failure levels of RIFLE. Stage 2 AKI is defined as an increase of 0.3
mg/dl serum creatinine and a drop in urine output below 0.5 mg/kg/hr for 12
hours.[5] In the clinic, patients are often diagnosed with AKI using a combination
of RIFLE and AKIN classifications determined by the Kidney Disease Improving
Global Outcomes (KDIGO) group. Diagnosis is based on either a 0.3 mg/dl
increase of serum creatinine within 48 hours or a doubling of serum creatinine
from estimated baseline occurring within 7 days.[5]
Biomarkers of AKI
Although serum creatinine has been relied on in clinics for diagnosing AKI,
it is not a perfect indicator. Serum creatinine does not become elevated until 2472 hours after a renal insult. It is also affected by factors such as age, race, sex,
body weight, metabolism, and protein intake.[2] BUN also has limitations in
determining GFR, as it is also affected by factors other than renal injury and
spikes after renal damage has already occurred.[4] As the incidence of AKI
development is increasing with an aging population, it has become more and
more important to develop new biomarkers with more sensitivity and specificity.
Ideally, new biomarkers would be more specific to kidney damage and would
indicate injury is occurring at earlier timepoints. Two newer biomarkers of AKI
include neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury
marker 1 (Kim-1).
3

NGAL gained attention as a biomarker of AKI when it was observed to be
elevated in the kidney following ischemic and nephrotoxic insults in animal
studies.[7] It was first identified in neutrophils, but it also functions as a rapid
response protein to tissue injury. NGAL has antibacterial effects through iron
scavenging properties and promotes epithelial growth through an unknown
mechanism.[8] NGAL has had mixed success in predicting AKI events clinically.
Although it is a sensitive marker for kidney tissue damage, it has also been
shown to elevate in other acute and chronic inflammatory conditions.
Development of an assay specific for kidney secreted NGAL would increase its
specificity as a marker of AKI.[7, 8]
Kim-1 is a cell surface receptor in epithelial and lymphoid/myeloid cells. Its
expression also increases significantly during AKI in proximal tubule cells.[8] It
has been suggested that during AKI, proximal tubule cells lose their polarity and
Kim-1 is secreted into the interstitium.[9] Although larger studies for validation are
needed, Kim-1 shows promise as a specific and sensitive marker for subclinical
AKI detection. It has been approved by the US FDA as a biomarker for preclinical
drug development.[10]
Pathology of AKI
There are many underlying causes of AKI. AKI can arise due to prerenal,
intrinsic, or postrenal conditions. Prerenal injury is due to decreased renal
prefusion or volume depletion. Intrinsic injury is caused by direct damage or
disruption within the kidneys. Postrenal injury occurs when there is insufficient
urine drainage distal to the kidneys. While prerenal and postrenal injuries can
4

often be corrected with repletion of intravascular volume or removal of a urinary
blockage, intrinsic AKI must resolve with time and often requires renal
replacement therapy such as dialysis.[11]
Intrinsic AKI is the most common form of AKI acquired in hospitalized
patients, accounting for up to 70% of cases.[4] Intrinsic injury is divided into
further categories based on where kidney damage is occurring. There are
glomerular, interstitial, tubular, and vascular causes of intrinsic AKI. AKI is most
often caused by acute tubular necrosis.[11] Eighty to ninety percent of the cases
of acute tubular necrosis are a result of an ischemic or nephrotoxic insult.
Despite the name, cell death is not always present in AKI caused by acute
tubular necrosis and can include damage caused by sublethal changes in tubule
cells. AKI involves several pathophysiological processes including endothelial
damage and vascular impairment, immune response, and tubular cell death.[12]
There processes orchestrate AKI development in phases of initiation, extension,
maintenance, and recovery.[4]
In the initiation phase, the ischemic or nephrotoxic insult causes functional
damage to tubule epithelial cells. Renal blood flow decreases as a result of
injury, causing a decrease in available cellular ATP. This limited energy supply
further damages epithelial and endothelial cells, triggering the release of
cytokines and chemokines to initiate the inflammatory cascade. Epithelial cells
will also undergo morphological changes, leading to a loss of the brush border
membrane and begin undergoing apoptosis or necrosis. After death, these cells
often slough off and cause tubular obstruction.[4]
5

The extension phase defines the subsequent continued hypoxia and
inflammatory response. Hypoxia is exacerbated by damage to renal vascular
endothelial cells. Inflammatory and profibrotic cells begin infiltrating and
proliferating in response to the earlier released signals. Tubule cells continue to
die in this phase, leading to a continued decline in GFR.[4]
In the maintenance phase, repair processes begin. GFR halts its decline
as tubule cells begin dedifferentiation, migration, and proliferation to re-establish
structural integrity. Renal blood flow begins to return to normal. Cellular repair
and reorganization begin the process of restoring organ function.[4]
In the recovery phase, renal function recovers. Epithelial cells re-establish
polarity and return to normal function. Inflammatory and profibrotic cells are
cleared. The extent to which renal function returns can vary depending on
several factors. It is also hypothesized that there may be chronic impairment of
vasculature and sublethal changes in tubule epithelial cells making the kidney
more sensitive to additional insults.[4]
Episodes of AKI can lead to many different outcomes. Acute symptoms
include disturbances in acid-base and electrolyte homeostasis, uremia, and fluid
overload.[3] Currently, there are no FDA approved agents to prevent or treat AKI.
Patients are often required to stay in the hospital to receive primarily supportive
care. Patients’ intravascular volume, electrolyte balance, and cardiac function are
closely monitored. In certain cases, fluid replacement therapy can be used to
correct imbalances.[11]
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Following an incident of AKI, the kidney has the ability to repair tissue
damage and return to normal function. However, long term studies have shown
that patients who have suffered an AKI event have increased risk of developing
chronic kidney disease (CKD), proteinuria, and cardiovascular mortality.[13] One
study found that development of AKI requiring dialysis made patients 28 times
more likely to develop CKD and doubled the risk of mortality.[14] As more
research is done, the link between AKI and CKD has become increasingly noted.

CHRONIC KIDNEY DISEASE
Epidemiology and Defining CKD
CKD is defined as a gradual loss of kidney function accompanied by
kidney damage, usually measured by albuminuria. CKD is typically accompanied
by interstitial fibrosis, glomerulosclerosis, and chronic inflammation.[13] A
diagnosis of CKD encompasses a diverse range of conditions with different
causes, severity, and rates of progression. Typically, CKD is diagnosed when
patients progress to the failure stage of the RIFLE classification and remain there
for over 3 months.[15] At this stage there is generally a 75% reduction in GFR.
Since no treatment is available for CKD, patients must be put on dialysis. This
can slow the progression of kidney disease, but patients will eventually progress
to loss of kidney function (complete loss of function for more than 4 weeks) and
then to end stage renal disease (complete loss of function for more than 3
months). Patients at this stage eventually require a renal transplant to survive.[5]
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CKD prevalence has been steadily increasing over the past 20 years.[16]
As of 2017, CKD was estimated to affect 13.4% of people globally.[17] In the US,
there is estimated to be 400 new cases of CKD per million people per year.[15]
This increasing prevalence is concerning due to the detrimental impact on
patients as well as the high societal cost of CKD. Generally, CKD development is
associated with old age, hypertension, diabetes, cardiovascular disease, and
obesity.[15] Recently, more studies have been done revealing that multiple
incidences of AKI also increase the likelihood of CKD development.[18, 19]
As mentioned earlier, AKI involves high levels of tubule cell death.
Following AKI, the kidney initiates normal wound healing processes to recover
from the initial insult. Although the repair processes following AKI can recover
renal function, in some cases the kidney undergoes what has been termed
maladaptive repair, which can lead to the development of CKD.[13]
Maladaptive Repair
Maladaptive repair refers to the phenomenon by which normal repair
processes go awry and result in progressive damage. The primary features of
maladaptive repair are cell cycle arrest, profibrotic cytokine production,
myofibroblast accumulation, chronic immune cell activation, and chronic vascular
impairment.[13] Maladaptive repair begins in the maintenance phase of AKI,
when tubule cells are beginning to respond to renal injury. In this stage, it has
been demonstrated that surviving tubule cells are pushed into the cell cycle in
order to proliferate and re-establish the proximal tubule structure.[20] This
adaptive proliferation is necessary for healing, but in maladaptive repair tubule
8

cells undergo G2/M cell-cycle arrest and senescence.[13] In this arrested state
tubule cells secrete profibrotic factors such as transforming growth factor beta
(TGFβ) and connective tissue growth factor (CTGF) downstream of c-Jun Nterminal kinase (JNK) activation.[12]
The process of cell-cycle arrest and subsequent JNK activation leading to
fibrosis has been primarily worked out in models of ischemia-reperfusion injury
(IRI). Yang et. al. demonstrated that pharmacologic inhibition of JNK as well as
p53 (preventing cell-cycle arrest) reduces fibrosis following ischemic injury. This
study also found that pharmacologic induction of G2/M cell cycle arrest in HK-2
cells increased JNK activation and upregulated profibrotic gene expression.[21]
These studies demonstrate that cell cycle arrest can lead to JNK activation and
cytokine production. It also illustrates that this process is involved in development
of renal fibrosis following ischemic injury.
The profibrotic cytokines produced by senesced tubule cells promotes
production of activated myofibroblasts.[12] A major hallmark of maladaptive
repair is the appearance of these activated myofibroblasts, which are the main
contributors of collagen deposition and development of the fibrotic matrix.[13]
Myofibroblasts display characteristics of both smooth muscle cells and
fibroblasts. In normal wound healing their role is to deposit ECM in order to
maintain the integrity or injured tissue, allowing for proliferation and healing. In
maladaptive repair, myofibroblasts are chronically stimulated leading to over
production of ECM. The ECM laid down in renal fibrosis is primarily composed of
type I and III collagen cross-linked by fibronectin.[22] Myofibroblasts have been
9

speculated to differentiate from several different precursors.[23] Although it is still
a subject with much controversy, resident fibroblasts and pericytes are thought to
be major contributors with mesenchymal stem cells and bone-marrow derived
fibrocytes also having a role.[13]
In addition to profibrotic cytokine production, injured tubule cells also
release pro-inflammatory cytokines and chemokines through mechanisms
including activation of toll-like receptor (TLR) signaling. TLRs are expressed on
tubule epithelial cells. Exogenous and endogenous ligands associated with injury
can activate the proinflammatory TLR response leading to production of tumor
necrosis factor alpha (TNFα), monocyte chemoattractant protein 1 (MCP-1), and
interleukin 6 (IL-6) to recruit immune cells to the injured kidney.[12] Neutrophils,
monocytes/macrophages, and leukocytes are among the most responsive
infiltrates to the kidney. These immune cells are important in the normal process
of recovery to attenuate early injury as well as clear damaged debris. However,
chronic immune cell activation can mediate effects of maladaptive repair,
particularly through chronically activated macrophages.[13]
Macrophages make up a large and diverse population of immune cells.
They are a group of phagocytic cells that differentiate from monocytes upon
environmental stimulation. In kidney injury, both renal resident and bone-marrow
derived infiltrating macrophages respond to injury. Resident macrophages arise
from embryonic macrophages that migrate to the kidney during development.
These resident cells help maintain renal homeostasis by clearing cellular debris
and aiding in tissue remodeling. Infiltrating macrophages are recruited to the
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kidney following injury. Both resident and infiltrating macrophages can adopt
different phenotypes to perform a variety of functions.[24]
Functionally speaking, macrophages display a spectrum of subtypes. For
simplicity, we will refer to the extreme ends of the spectrum as M1 and M2. M1
macrophages appear in the kidney rapidly following injury. These cells are
generally considered “pro-inflammatory.” Macrophages are polarized to an M1
phenotype by pro-inflammatory cytokines and danger signals.[25] Upon
polarization, they continue to produce proinflammatory cytokines to recruit other
immune cells. They also produce reactive oxygen and nitrogen species to
destroy pathogenic particles. This is done largely by inducible nitric oxide
synthase (iNOS) which is a characteristic marker of M1 function.[24] M1
macrophages are thought to play a role in infection clearance, but they are also
known to exacerbate acute renal injury.[25]
M2 macrophages appear later in kidney injury and are thought of as
having a “pro-repair” phenotype. There are several different subsets of M2
macrophages that differentiate in response to different environmental stimuli.
TGFβ is one of the major cytokines that drives M2 polarization. M2 macrophages
are thought to suppress inflammation and promote tissue repair.[25] Arginase-1
(Arg-1) is characteristically expressed by M2 macrophages and is used to
produce building blocks for the ECM. M2 macrophages also secrete TGFβ
creating a positive feedback signaling loop.[24] Although M1 macrophages may
still be present in chronic injury, development of renal fibrosis is associated with
an M1 to M2 phenotype transition.[25]
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The complex role of macrophages in kidney injury has been studied by
several groups. In a model of IRI it was demonstrated that global depletion of
macrophages via administration of liposome clodronate attenuated development
of renal fibrosis. Adoptive transfer of M2 macrophages after global depletion
reversed this beneficial effect while M1 transfer did not. This suggests a role for
M2 macrophages in the development of fibrosis post-IRI.[26] Another study went
on to demonstrate that global depletion of macrophages with liposomal
clodronate after development of AKI following IRI resulted in failure to recover
from injury.[27] These studies demonstrate the importance of coordinated M1
and M2 responses to kidney injury to promote proper healing and repair. Chronic
activation of either subset likely can exacerbate maladaptive repair processes.
The immune cell responses and wound healing processes observed after
a renal insult suggests repairing tubule structure is the most immediate response
to kidney injury. However, removing causes of injury is also of high importance in
recovery from AKI. As mentioned earlier, vascular endothelial damage in AKI
leads to renal hypoxia. In the extension phase of AKI, this endothelial injury and
dysfunction leads to continued impairment of kidney oxygen delivery. Studies
show repeated injury promoting tubule cell proliferation may impede the repair of
endothelial cells. Tubule proliferation is associated with high levels of TGFβ and
low levels of vascular endothelial growth factor (VEGF) in the kidney.
Differentiation of pericytes into myofibroblasts trigged by damaged tubule cells
also removes vital trophic support of endothelial cells. This suggests that tubular
repair may inadvertently impair vasculature repair.[13] Repeated AKI insults and
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maladaptive repair therefore also lead to chronically impaired vasculature, further
promoting renal fibrosis.
All the above processes demonstrate how maladaptive repair can result
from a chronic activation of injury responses. Endothelial damage promotes
continued injury leading to tubule G2/M cell-cycle arrest, profibrogenic cytokine
production, chronic immune cell activation, and activation of myofibroblasts.
These processes promote chronic inflammation, fibrosis, and vascular rarefaction
characteristic of CKD.[13]
Fibrosis and Resolution
Fibrosis is defined as an excessive accumulation of ECM commonly
caused by chronic or repeated injury. Excessive ECM deposition disrupts tissue
architecture and decreases renal function.[22, 28] Typically, ECM production is a
normal part of wound healing. It is vital to maintaining tissue integrity following an
injury. Improper resolution of fibrosis is what leads to chronic disease. Wound
healing can be defined in phases that involve the same processes as
maladaptive repair up until the final phase. The inflammatory phase refers to the
death of tubule cells prompting infiltration of immune cells to clear debris and
promote new tissue formation.[22] The proliferative/effector phase involves the
proliferation of tubule cells to reestablish barrier function as well as the
differentiation and proliferation of myofibroblasts to produce ECM and maintain
tissue integrity. The final phase of wound healing is maturation. In this stage, the
ECM is degraded and profibrogenic myofibroblasts are removed. Repeated or
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chronic injury often leads to inadequate maturation, resulting in long term organ
fibrosis.[28]
It should be noted that there are two main forms of ECM: basement
membrane ECM and interstitial ECM. Basement membrane ECM provides
support for epithelial and endothelial cells. It is made up of collagen IV and
laminins. Interstitial ECM is secreted primarily by myofibroblasts and has a more
rigid, cross-linked structure. Interstitial ECM is thought to be more fibrotic, made
up of fibrillar collagen type I and III cross-linked by fibronectin. Basement
membrane and interstitial ECM are thought to play different roles in the
development of renal fibrosis.[22]
Resolution of organ fibrosis in the maturation phase requires three
components: eradicating the cause of injury, degradation and removal of the
fibrotic ECM, and elimination of myofibroblasts.[22, 28] Promoting resolution of
organ fibrosis to treat CKD is a rising area of research. One mechanism for
targeting resolution of fibrosis is increasing the degradation of ECM. A potential
mechanism for increasing the degradation of ECM is through metalloproteinases
(MMPs). MMPs are thought to be the most important enzymes involved in
collagen degradation. They comprise a large family of proteins. Although MMPs
are important in degradation of fibrotic matrix, they can also promote fibrosis
through activities unrelated to ECM degradation.[22]
The role of MMPs in renal fibrosis is not straight forward. Nishida et. al.
examined the role of matrix metalloproteinase 2 (MMP2) in development of renal
fibrosis following unilateral ureteral obstruction. They found that pharmacologic
14

inhibition of MMP2 attenuated development of fibrosis. Interestingly, MMP2
inhibition also lead to decreased macrophage infiltration in the injured kidney.
This was hypothesized to be the mechanism of protection.[29]
Wang et. al. also demonstrated that mice lacking matrix
metalloproteinase-9 (MMP9) developed less fibrosis in a model of unilateral
ureteral obstruction. MMP9 knockout mice displayed less disruption of tubule
basement membrane following injury. They also had decreased expression of
fibronectin and less total collagen. They hypothesized that MMP9 deficiency
provided protection primarily by preventing basement membrane
degradation.[30] Other studies on MMP9 have led to the hypothesis that MMP9
degradation of basement membrane ECM promotes tubule epithelial to
myofibroblast transition. Promoting this differentiation suggests that MMP9 plays
a profibrogenic role.[31, 32]
Other studies have also demonstrated the complexity of MMPs in renal
fibrosis. Another strategy that has been tried to promote fibrotic ECM degradation
is inhibition of tissue inhibitors of metalloproteinases (TIMPs). TIMPs bind to
MMPs and target them for macrophage engulfment, preventing their activity.[22]
Kawamoto et. al. used TIMP3 knockout mice in a model of unilateral ureteral
obstruction. Although these mice had some alterations in kidney structure, TIMP3
deficiency did not prevent development of renal fibrosis.[33]
These studies indicate that MMPs and TIMPs play multiple roles in the
kidney besides regulating degradation of fibrotic ECM. The balance of MMPs and
TIMPs can regulate immune cell responses, myofibroblast accumulation, and
15

signaling pathways such as TGFβ. It is clear that MMPs and TIMPs serve
purposes beyond degradation of ECM. Our lack of understanding of their many
complex roles make them a difficult target for prevention of renal fibrosis.[28]
As myofibroblasts are thought to be the source of increased ECM in
development of fibrosis, eliminating myofibroblasts is another area of focus.
Myofibroblasts may be removed via apoptosis, senescence, dedifferentiation, or
reprogramming.[22] Zeisberg et. al. attempted to promote myofibroblast
dedifferentiation to attenuate renal fibrosis in a nephrotoxic serum nephritis
model. This group used bone morphogenic protein 7 (BMP-7), a member of the
TGFβ superfamily, in an attempt to reverse the epithelial to myofibroblast
transition occurring in progressive renal disease. In vitro they demonstrated that
BMP-7 reversed TGFβ-induced changes in tubule epithelial cells. They therefore
hypothesized that BMP-7 was promoting processes that opposed the epithelial to
myofibroblast transition and would be capable of preventing myofibroblast
accumulation. They then demonstrated that BMP-7 treatment in vivo slowed
progression of renal fibrosis, but it could not reverse disease pathogenesis.[34]
Although this study showed promise, the plasticity of myofibroblasts make them a
difficult target for treatment.
Although fibrosis shows potential for resolution in the context of wound
healing, it is accepted that all organs have a “point of no return” in which capacity
for resolution is lost. In most clinical cases, the attempts to reverse developed
organ fibrosis have not had much success.[28] Targeting the extension phase of
AKI seems to hold the most potential for preventing the AKI to CKD transition.
16

Currently, there is no cure for CKD. As CKD is a progressive disease, most
therapies are aimed at supportive care and slowing the progression of functional
decline. Medication aimed at blood pressure and glycemic control are commonly
used.[35] Even with these treatments patients will eventually progress to endstage renal disease.

CISPLATIN
Clinical Uses of Cisplatin
As previously mentioned, the most common cause of intrinsic AKI is acute
tubular necrosis caused by ischemic or nephrotoxic insults. Nephrotoxic side
effects of drugs cause around 20% of hospital and community acquired AKI
cases.[36] One of the most common class of agents that induce nephrotoxic
acute tubular necrosis is nephrotoxic chemotherapies.[11] It is estimated that
60% of hospital-acquired AKI is caused by nephrotoxicity of chemotherapy.[37]
Cisplatin (cis-diamminedichloridoplatinum(II)) is an inorganic platinumbased drug that was approved by the FDA as an anticancer agent in 1978.[38] It
is currently a standard component of therapy used to treat many solid-organ
cancers such as head, neck, lung, testis, ovary, and breast.[39] The major
mechanism of action of cisplatin involves binding DNA, forming adducts, and
forcing cancer cells to undergo apoptosis or cell-cycle arrest. It has shown a
great amount of success as an anticancer agent, particularly in treating testicular
and ovarian cancer. Since the FDA approval of cisplatin, the rate of remission for
17

testicular cancer has increased from 5% to around 80%.[38] The effectiveness of
cisplatin however, is largely reduced by its dose-limiting nephrotoxicity.
In an effort to bypass this toxicity, several analogs of cisplatin such as
carboplatin and oxaliplatin have been developed. Although these compounds do
have less nephrotoxicity, they are much less effective in killing many types of
cancer cells. One study demonstrated that the concentration of carboplatin had
to be 20-40 fold higher than that of cisplatin to form the same amount of DNA
adducts.[38] Due to its high level of activity, cisplatin is still commonly used in the
clinic today.
Around 30% of patients who receive cisplatin develop AKI.[39] Since there
are no approved agents to treat AKI, development of the injury requires treatment
to be suspended. Patients are monitored in hopes that renal function will recover
in 2-4 weeks. Following recovery, patients are often switched to a different
treatment regimen.[39] The nephrotoxicity associated with cisplatin prevents it
from being as effective in treating cancer as it could be. Since its approval,
research has shed light on the mechanism of cisplatin’s nephrotoxicity in hopes
of finding a way to prevent these effects.
Mechanisms of Nephrotoxicity
Patients typically receive cisplatin as either a bolus intravenous injection
or slow intravenous infusion.[40] As the kidney receives a large portion of blood
flow, it encounters high concentrations of cisplatin. Cisplatin is filtered from the
blood into the kidney through both glomerular filtration and tubular secretion. As
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the blood is filtered by the kidney, active accumulation of cisplatin within renal
parenchymal cells occurs. Cisplatin concentrations eventually become greater in
the kidney then in the blood.[39]
The high affinity copper transporter (Ctr1) and the organic cation
transporter (OCT2) are both highly expressed basolaterally on proximal tubule
cells and facilitate the uptake of cisplatin by the kidney.[41] While Ctr1 is
ubiquitously expressed, OCT2 has much higher levels of renal expression.[37]
Ctr1 has been shown to facilitate uptake of cisplatin by cancer cells, making it a
poor target for prevention of renal toxicity.[41] OCT2 expression is more specific
to renal tubule cells and studies have demonstrated that OCT2 knockout and
pharmacologic inhibition with cimetidine confers some resistance to cisplatininduced kidney injury.[42, 43] Additional studies also demonstrated that coadministration of cisplatin with cimetidine did not affect antitumor efficacy.[44] On
the apical membrane, multidrug and toxin extrusion 1 (MATE1) is expressed and
is capable of transporting cisplatin from tubule cells into the lumen for excretion.
Studies have shown that MATE1 knockout mice are more sensitive to AKI and
have elevated levels of platinum in the kidney following high-dose cisplatin
treatment.[45]
Prior to transport, metabolism of cisplatin begins in circulation with
glutathione conjugation, possibly by glutathione-S-transferase.[39, 41] These
conjugates are then cleaved by gamma glutamyl transpeptidase (GGT) to form
cysteinyl-glycine-conjugates.[39] Some studies have demonstrated the inhibition
of glutathione-S-transferase and GGT can attenuate cisplatin nephrotoxicity in
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mice, but the effect on tumoricidal activity is unknown.[37] Aminopeptidases
further metabolize cisplatin by cleaving it into a cysteine conjugate. The cysteine
conjugate is then transported into proximal tubule cells where it is converted to a
highly reactive thiol by cysteine-S-conjugate-beta-lyase.[37, 39]
As mentioned above, the primary mechanism of cisplatin’s anti-cancer
activity is thought to be through DNA damage. Several studies have further
demonstrated that mitochondrial DNA is the major target of damage.[39] In
aqueous environments cisplatin exchanges its chloride ions for water molecules,
forming a positively charged electrophile. This can lead to preferential
accumulation in negatively charged mitochondria.[39, 46] Nevertheless,
accumulation of reactive cisplatin metabolites in the cell leads to formation of
DNA, RNA, and protein adducts.[47] These adducts contribute to nephrotoxicity
via many of the same mechanisms by which cisplatin kills cancer cells. Cisplatininduced nephrotoxicity involves proximal tubule cell damage, increased oxidative
stress, inflammatory response, and vascular injury.[41, 47]
Cisplatin induces proximal tubule cell damage via several mechanisms.
The most prominent mechanism of injury is activation of cell death pathways.[39,
41, 47] Cisplatin has been demonstrated to induce necrosis as well as intrinsic-,
extrinsic-, and endoplasmic reticulum (ER) stress associated pathways of
apoptosis.[41, 47] Wei, Dong, & Dong demonstrated the importance of intrinsicapoptotic signaling in cisplatin nephrotoxicity using genetic manipulation of proapoptotic BCL-associated X (BAX). They demonstrated that BAX knockout
conferred resistance to cisplatin-induced kidney injury in mice by decreasing
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cytochrome c release and the number of apoptotic cells.[48] This study indicates
that tubule cell intrinsic apoptosis is a large contributor to nephrotoxicity.
Wei et. al. went on to demonstrate a role for tumor protein 53 (p53) in
intrinsic apoptosis induction in cisplatin nephrotoxicity. p53 has been known to
play a role in apoptotic induction following DNA damage. Their group observed
that cisplatin treatment lead to increased phosphorylation of p53. They then
showed that inhibition of p53 with piﬁthrin-α and genetic deletion of p53
attenuated cisplatin-induced kidney injury in mice.[49] This study demonstrates
that DNA damage is likely a major contributor to intrinsic apoptotic induction in
cisplatin nephrotoxicity.
Cisplatin has also been reported to promote cell death independently of its
DNA damaging actions. Mandic et. al. observed nucleus-independent apoptotic
signaling triggered by cisplatin. When enucleated cells were treated with
cisplatin, ER stress was induced. This ER stress then triggered caspase
activation and apoptosis. Other DNA damaging agents were not able to induce
this same response, indicating that cisplatin had unique cytosolic targets.[50]
Cisplatin-induced tubular damage sets off the pathological processes of AKI
discussed earlier.
Cisplatin induces many other forms of sublethal damage involving cell
cycle dysregulation, activation of mitogen activated protein kinase (MAPK)
signaling, mitochondrial dysfunction, ER stress, and autophagy induction.[39, 41,
47] ER stress and autophagy are of particular relevance to this work. ER stress is
caused by an accumulation of misfolded proteins. Cisplatin has been speculated
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to cause ER stress through adduction to cytosolic targets.[50] The level and
duration of ER stress determines if cells are forced to undergo apoptosis or to
adapt and survive. One method of adapting to ER stress is through upregulation
of autophagy.[51] Autophagy is a form of cellular “self-eating” that can be both
protective and detrimental. Studies have shown that cisplatin-induced AKI is
associated with induction of autophagy. In acute models of injury this induction is
thought to be protective.[47] Autophagy can help reduce levels of cisplatininduced apoptosis by ameliorating effects of cellular damage from oxidative
stress and mitochondrial dysfunction.[52] In chronic kidney injury the role of
autophagy is more controversial. It has been argued that long-term upregulation
of autophagy could also contribute to renal damage.[53] These mechanisms of
sublethal damage demonstrate that even if cisplatin does not induce cell death, it
can still have negative impacts on cellular homeostasis.
Inflammation is another mediator of cisplatin nephrotoxicity that has been
repeatedly studied in cisplatin-induced kidney injury (CDDP-KI). Cisplatin
treatment is associated with an upregulation of many different proinflammatory
cytokines and chemokines such as interleukin 1 beta (IL-1β), IL-6, MCP-1, and
TNFα.[41, 47] One mechanism of production of these signals is via toll-like
receptor signaling. Injury to renal epithelial cells induces release of damage
associated molecular patterns (DAMPs) which activate toll-like receptor 4
(TLR4). TLR4 activation leads to production of chemokines and cytokines,
including TNFα, that lead to upregulation of endothelial adhesion molecules and
attraction of inflammatory cells.[39] Ramesh and Reeves have shown that TNFα
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is a major inflammatory mediator in CDDP-KI. They utilized TNFα knockout mice
and GM6001, a pharmacological inhibitor of TNFα, to demonstrate that inhibition
of TNFα signaling attenuated CDDP-KI. They also demonstrated that TNFα
inhibition decreased production of other inflammatory mediators, indicating it
plays a central role in activation of the cytokine response.[54] The cytokine
response attracts immune cell infiltrates to the injured kidney. Neutrophils,
macrophages, T cells, and dendritic cells appear to be the largest responders to
cisplatin induced injury.[39, 47]
Vascular damage is another mediator of CDDP-KI. This damage is
orchestrated in a variety of ways including alteration of renal blood flow and
direct toxicity to endothelial cells.[47] Early vasoconstriction in response to
cisplatin has been thought to be an initiator of vascular injury. Although the cause
of vasoconstriction is not quite clear, it results in a decrease in GFR and
promotes development of a hypoxic environment. Hypoxic conditions further
contribute to the tubule cell death and inflammation. Vascular damage, tubule
cell death, and inflammation are all connected and work together to orchestrate
the nephrotoxicity of cisplatin.[4]
The nephrotoxicity of cisplatin has been observed in patients since its
introduction. Many strategies have been applied to prevent this toxicity from
occurring. Hydration regimens and use of diuretics such as furosemide and
mannitol have been explored. Clinically, however, these regimens do not seem to
prevent CDDP-KI. Current clinical guidelines recommend pre-hydration with
0.9% saline and avoidance of diuretics.[39]
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Models of Cisplatin Injury
As previously mentioned, 30% of patients who receive cisplatin develop
AKI. They display a rapid decline in kidney function and increase in BUN or
serum creatinine following treatment. This type of CDDP-KI is modeled in animal
studies by using a single high dose (10-30 mg/kg) of cisplatin. Following
treatment, mice display a significant decline in renal function and typically only
survive 3-4 days post treatment. This model mirrors the rapid decrease in GFR
and spike in serum creatinine defining AKI in the clinic. However, it does not
allow for long term studies of the effects of CDDP-KI.[38, 55]
70% of patients who receive cisplatin do not develop AKI by clinical
criteria. Recent studies have revealed that these patients may still be at risk for
long term renal effects from cisplatin. Skinner et. al. followed pediatric patients
treated with cisplatin that did not develop clinical AKI. They found that 10 years
following treatment 11% had a decreased GFR and 15% were showing signs of
nephrotoxicity.[56]
In order to address this issue, Sharp et. al. developed a new animal model
to study CDDP-KI. This model involves repeated low doses of cisplatin (7-9
mg/kg) once a week for four weeks. Mice treated with this dosing regimen can
survive 6 months following treatment. Immediately following treatment mice do
not show significant increases in BUN; however, at 6 months post-treatment mice
do have significantly elevated BUN levels compared to vehicle treated mice. This
indicates mice have progressive loss of kidney function following cisplatin
treatment without showing clinical signs of AKI during the dosing window.[57]
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These models together allow us to study patients on either end of the
CDDP-KI spectrum. The acute, high dose model is characterized by high levels
of tubular apoptosis and necrosis, a rapid decline in GFR, and increases in BUN
and serum creatinine. On the other hand, the chronic, low dose model does not
cause significant BUN or serum creatinine changes. This model seems to cause
subclinical injury that leads to development of fibrosis following the fourth dose.
Fibrosis worsens as mice age to 6 months post treatment, accompanied by a
chronic infiltration of macrophages. This phenotype is more indicative of CKD
development.[58]
Together these models demonstrate the interconnectedness of AKI and
CKD and how cisplatin can lead to both types of kidney injury. These models
also depict how different biological processes can be triggered in response to
acute or chronic cisplatin treatment. Both models should therefore be used to test
drug candidates to prevent CDDP-KI.

SPHINGOLIPIDS AND KIDNEY INJURY
Sphingolipid Metabolism
Sphingolipids are lipid compounds that contain a sphingoid-base
backbone. The kidney has been known to play an important role in sphingolipid
metabolism for many years. It was originally thought that sphingolipids played
primarily a structural role in the cell. It has since come to light that sphingolipids
act on a number of cellular targets and are involved in many different signaling
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pathways.[59] It has become an increasing area of interest to examine how these
bioactive lipids effect renal physiology and how regulation of lipid levels could be
used as a therapeutic target.[60]
Sphingolipid metabolism involves an abundance of enzyme-catalyzed
reactions. At the center of this large network lies ceramide. Ceramide can be
produced via de novo synthesis, sphingomyelin hydrolysis, or recycling of other
complex sphingolipids. In de novo synthesis, serine palmitoyl transferase
condenses serine and palmitoyl CoA to form 3-ketosphingosine. This product is
then reduced to dihydrosphingosine by 3-ketoreductase. Dihydrosphingosine is
then acylated by ceramide synthase to form dihydroceramide. Desaturase then
desaturates dihydroceramide at the 4-5 position of the sphingoid base backbone
to generate ceramide. Once generated, ceramide is the basis for several
reactions generating other bioactive lipid species.[59, 61]
Ceramide can be used by sphingomyelin synthases to form
sphingomyelin. It can also be phosphorylated by ceramide kinase to form
ceramide-1-phosphate. Glycosylation of ceramide via addition of a glucose or
galactose forms the hexosylceramides, glucosylceramide, and
galactosylceramide, respectively. Hexosylceramides are utilized to synthesize
more complex gylcosphingolipids and can also be broken down to regenerate
ceramide. Ceramide can be cleaved via the action of ceramidases to form
sphingosine, which can then be phosphorylated by sphingosine kinases 1 or 2 to
form sphingosine-1-phosphate (S1P). Sphingosine can also be recycled back
into ceramide as catalyzed by ceramide synthases or ceramidases. In our
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studies, we focus on the balance of ceramide, sphingosine, and S1P. It is
thought that the balance of these bioactive sphingolipids regulates several
cellular processes including inflammation, reactive oxygen species production,
and cell death. These are all processes implicated development of acute kidney
injury and chronic kidney disease.[59, 61]
Manipulation of Sphingolipids in Models of Kidney Injury
Ceramide has been considered a “pro-apoptotic” signaling lipid in the
past.[59] In vitro, cisplatin treatment of baby mouse kidney epithelial cells
induces ceramide generation via upregulation of de novo ceramide synthesis.
Inhibition of ceramide synthesis protected these cells from cisplatin-induced cell
death.[61] Our studies have also demonstrated that acute cisplatin treatment
causes increased levels of ceramide in the kidney.[62] Taken together, these
studies suggest that ceramide could be a key mediator of cisplatin-induced cell
death in kidney injury.
Dupre et. al. used this rationale to explore the impact of inhibiting
ceramide synthesis on kidney injury caused by acute cisplatin treatment. In this
study, it was also observed that there were increased activities of ceramide
synthases in the de novo synthesis pathway and acid sphingomyelinase in the
kidney cortex following treatment of mice with cisplatin. Therefore, ceramide
synthesis was inhibited via myriocin and amitriptyline, inhibitors of de novo
ceramide synthesis and acid sphingomyelinase, respectively. These inhibitors
reduced ceramide levels in the kidney following cisplatin treatment. This inhibition
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also resulted in lower levels of BUN and serum creatinine following single, high
dose cisplatin.[62]
Dupre et. al. also noted that there were increased levels of
hexosylceramides in the kidney following cisplatin treatment of mice. It had been
unknown whether ceramide or the shuttling of ceramide into hexosylceramides
was promoting CDDP-KI. C10, an inhibitor of glucosylceramide synthase, was
used to prevent this shuttling of ceramide into hexosylceramides. C10 and
cisplatin co-treatment of mice lead to increased levels of BUN, Kim-1, and tissue
damage. C10 also caused increased apoptosis, cell proliferation, and
inflammatory cytokine production following cisplatin treatment. C10 and cisplatin
co-treatment prevented hexosylceramide generation, but increased ceramide
accumulation.[62] These data suggest a role for ceramide in apoptosis in CDDPKI. It also provides an example of how regulating the balance of different
sphingolipid species can affect CDDP-KI.
Other groups have also explored the role of sphingolipids in acute kidney
injury. The Okusa lab explored the role of S1P in kidney injury. S1P is known to
bind to and signal through a family of G-coupled protein receptors known as S1P
receptors (S1PRs). S1PR signaling was shown to be protective in models of
acute cisplatin injury and IRI. A S1PR agonist offered protection from kidney
injury in these models while genetic S1PR deletion exacerbated injury.[63, 64]
Bartles et. al. also demonstrated the importance of SIP signaling in IRI. They
subjected mice with endothelial specific S1PR deletion to ischemic injury. These
mice sustained higher levels of injury then wild type controls. This study
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highlights the importance of S1PR in endothelial function.[65] These studies
demonstrate the importance of S1P signaling pathways in renal injury.
The homeostasis of ceramide and other sphingolipids in the context of
kidney injury is becoming increasingly recognized. In this study, we evaluate the
effects of neutral ceramidase inhibition in the context of kidney injury both in vitro
and in vivo. Neutral ceramidase (nCDase) is one of five ceramidases. It is named
because it is most active at neutral pHs.[66] Although the role of nCDase in
kidney injury has not received much attention, it has been identified as a target in
other models of injury. Novgorodov et. al. demonstrated that nCDase inhibition
conferred protection from traumatic brain injury by protecting cells from
mitochondrial damage.[67] In the kidney, nCDase activity was shown to be
elevated in models of diabetic neuropathy.[68] Taken together, these studies
indicate that nCDase could play a pathological role in kidney injury via alteration
of ceramide, sphingosine, and S1P balance.
Our lab demonstrated that mouse embryonic fibroblasts (MEFs) lacking
functional nCDase were protected from nutrient and energy deprivation induced
cell death. nCDase knockout cells could survive cell stress due to increased
levels of autophagy.[69] It has been demonstrated that autophagy plays a
protective role in acute cisplatin-induced renal injury.[70] We therefore
hypothesized that nCDase inhibition may have some effect on CDDP-KI
development.
With the growing body of knowledge delineating the AKI to CKD transition
it has become increasingly important to test prospective nephroprotective targets
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in models of both acute injury and fibrosis development. In this study we set out
to examine how nCDase inhibition affects kidney injury following both the acute
high-dose cisplatin model and the repeated low dose cisplatin (RLDC) model.
Our results indicate that repeated low dose cisplatin treatment may utilize unique
mechanisms of injury to promote CKD development.
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MATERIALS AND METHODS
Cell Culture
Mouse embryonic fibroblast (MEFs) were generated and validated as previously
described from either wild type or neutral ceramidase (nCDase)-null C57BL/6
mice that were littermates.[69] Cells were immortalized with dominant-negative
p53. MEFs were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS) and supplemented with L-glutamine,
penicillin, streptomycin, and ciprofloxacin (Invitrogen). All cells were incubated at
37°C in 5% carbon dioxide. Cells were not cultured for more than 30 doublings
and were routinely assessed for mycoplasma using MycoSensor PCR assay kit
(#302108, Agilent Technologies) according to the manufacturer’s protocol.
Cell Viability Assays
For the FBS withdrawal experiment, cells were plated in DMEM containing 10%
FBS and antibiotics into 3 separated 96-well plates on day 1. On day 2, cells
were washed with sterile phosphate buffered saline (PBS) and then treated with
media at varying concentrations of FBS. On day 3, 1 plate was assessed for 24hour viability using Alamar Blue assay. On day 4, the 48-hour plate was
assessed and on day 5, the 72-hour plate was assessed. For the nCDase
inhibitor viability assay cells were plated, treated, and assessed in the same
manner. C6-urea-ceramide (C6) and the nCDase inhibitor from Ono
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Pharmaceutical Company (Ono) were dissolved in dimethyl sulfoxide (DMSO)
and added to DMEM at indicated concentrations. Final DMSO concentration in
media was kept under 1%.
nCDase in vitro TLC Activity Assay
Equal amounts of recombinant nCDase (gifted from Dr. Yusef Hannun, Stony
Brook University) were incubated and treated with the indicated nCDase
inhibitors at 0.1 μM to 100 μM. NBD-ceramide at 50 μM in 100 mM Tris with
0.3% Triton-X-100, pH 7.5 was added to each sample. The reaction progressed
for 10 minutes and was then stopped with 3:1 addition of equal parts
MeOH:Chloroform. Samples were centrifuged at 15,000 rpm for 10 minutes at
4°C. The organic phase of the reaction was extracted and dried down in a speed
vacuum. Samples were then solubilized in 10 μL of 1:1 MeOH:Chloroform and
spotted on a TLC plate. The plate was placed in a reaction chamber with
90:29.5:0.5 Chloroform:MeOH:NH4OH for 1 hour to allow separation of ceramide
and sphingosine. Plates were imaged with phosphoimager and analyzed using
Quantity One software. This assay was modified from Tani et. al.[71]
Animals
Neutral ceramidase knockout mice (nCDase-/-) were gifted from Dr. Ashley
Snider at Stony Brook University. nCDase-/- were originally generated in the
laboratory of Dr. Richard L. Proia (NIDDK, National Institutes of Health). These
mice were previously backcrossed for 10 generations onto a C57BL/6
background. nCDase-/- mice were bred in-house and all experiments were
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performed at 8-10 weeks of age. Wild type mice (C57BL/6, male, 4-weeks old)
were either bred in house or purchased from The Jackson Laboratory and
allowed to acclimate for 4 weeks prior to initiation of experiments. All mice were
maintained on a 12-hour light/dark cycle and provided food and water ad libitum.
All animal procedures were approved by the Institutional Animal Care and Use
Committee and followed the guidelines of the American Veterinary Medical
Association.
Cisplatin Dosing Regimen
Pharmacy grade cisplatin (1mg/mL in normal saline) was obtained from the
University of Louisville Hospital pharmacy. For the high-dose study, cisplatin was
administered at 20 mg/kg in normal saline in a total volume of 500 μL by
intraperitoneal (i.p.) injection. Vehicle treated mice received 500 μL normal saline
by i.p. injection. For the repeated low dose study, cisplatin was administered at 9
mg/kg in normal saline in a total volume of 400 μL by i.p. injection once a week
for four weeks. Vehicle treated mice received 400 μL normal saline by i.p.
injection once a week for four weeks. All mice were administered 500 μL saline
by subcutaneous injection 1 day prior to dose 3, 2 days after dose 3, and 1 day
before dose 4 to prevent weight loss. All animals were injected with cisplatin at
the same time of day as there are circadian influences on the response of the
kidney to cisplatin. Animals were euthanized 72 hours following their final
cisplatin injection. Upon euthanasia, blood was collected and plasma prepared
and frozen at -80°C; urine was collected and frozen at -80°C; and kidneys were
removed, flash frozen in liquid nitrogen, and stored at -80°C until use. A cross33

section of one kidney was also fixed in 10% neutral buffered formalin for
histology.
Blood Urea Nitrogen (BUN), Serum Creatinine (SCr), and Neutrophil
Gelatinase Associated Lipocalin (NGAL) Determination
BUN (AMS Diagnostics, 80146) and SCr (Point Scientific Inc., C7548-120) levels
were measured from plasma samples using the indicated kits following the
manufactures’ instructions. ELISAs for NGAL (R&D Systems, DY1857) were
performed on the urine as directed by the manufacturer.
Protein Quantification and Western Blot Analysis
Kidney tissue and cultured MEF cell pellets were homogenized in cell extraction
buffer (Thermo Fisher Scientific) containing a Complete Protease Inhibitor
Cocktail Tablet and Phosphatase Inhibitor Cocktail Tablets (Roche).
Homogenates were centrifuged at 15,000 X g for 10 min at 4° C. Supernatants
were removed and stored at -80°C. Protein concentrations were determined
using Bradford Reagent (Bio-Rad). 40 μg of kidney homogenate protein and 20
μg of MEF cellular protein were loaded and separated on 4–12% gradient TrisGlycine-SDS polyacrylamide gels. Protein was then transferred to PVDF
membranes that were blocked in 5% (w/v) dried milk in tris buffered saline 0.1%
Tween 20 (TBST) for 1 hour. Membranes were incubated with primary antibody
overnight at 4°C. The next morning, membranes were washed 3 times for 5 min
each with TBST containing 5% (w/v) dried milk. Membranes were then incubated
for 2 hours at room temperature with secondary antibodies conjugated with
horseradish peroxidase (1:20,000) in TBST containing 1.25% (w/v) dried milk.
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Following 3 washes in TBST membrane proteins were detected by
chemiluminiscence substrate.
Antibodies
The following antibodies were purchased from Cell Signaling (Beverly, MA):
cleaved caspase-3 (CC3) #9664, C/EEBP homologous protein (CHOP) #2895,
phosphorylated c-jun n-terminal kinase (p-JNK T183/Y185) #4668, c-jun nterminal kinase (JNK) #9258 and #9252, phosphorylated-protein kinase B (p-AKT
S473) #4060, protein kinase B (AKT) #4691, phosphorylated-glycogen synthase
kinase beta (p-GSK3β S9) #9322, glycogen synthase kinase beta (GSK3β)
#9315, phosphorylated nuclear factor kappa-light-chain-enhancer of activated B
cells (p-NF-κB S536) #3033, nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) #3987, phosphorylated- eukaryotic initiation factor 2
alpha (p-eIF2α) #3398, and light chain 3B (LC3B) #3868. Remaining antibodies
include: fibronectin (F3648, Sigma-Aldrich), α-tubulin (SC-23948, Santa Cruz
Biotechnology), and β-actin (A2228, Sigma-Aldrich).
Gene Expression
RNA was isolated using either TRIzol (Thermo Fisher Scientific) or E.Z.N.A. Total
RNA Kit 1 (OMEGA) per manufacturer’s protocol. cDNA was synthesized with
High Capacity cDNA Reverse Transcriptase PCR (Thermo Fisher Scientific) per
manufacturer’s instructions. Gene-speciﬁc cDNA was quantiﬁed with real-time
qRT-PCR using either predesigned TAQman assays or self-designed SYBR
assays. The following TAQman primers were purchased from Thermo Fisher

35

Scientific: tumor necrosis factor alpha (TNF-α, Mm00443258_m1), interleukin-6
(IL6, Mm00446190_m1), chemokine (C-X-C Motif) ligand 1 (CXCL1,
Mm04207460_m1), monocyte chemotactic protein (MCP-1, Mm00441242_m1),
arginase-1 (Arg-1, Mm00475991_m1), and the housekeeping gene beta-2microglobulin (B2M, Mm00437762_m1). The following primers were selfdesigned: inducible nitric oxide synthase (iNOS, Invitrogen, forward:
GAGATTGGAGGCCTTGTGTCA, reverse: TCAAGCACCTCCAGGAACGT) and
kidney injury molecule-1 (Kim-1, Invitrogen, forward:
AGATCCACACATGTACCAACATCAA, reverse:
CAGTGCCATTCCAGTCTGGTTT). qRT-PCR was done with either iTaq
Universal Probes Supermix (172-5134, Bio-Rad) or iTaq Universal SYBR Green
Supermix (172–5124, Bio-Rad).
Histology
Following formalin fixation, kidney tissue was processed and embedded in
paraffin. Kidney sections (5 m) were stained with hematoxylin and eosin (H&E)
and periodic acid schiff (PAS). The degree of morphologic changes was
determined by light microscopy in a blinded fashion. The following measures
were chosen as an indication of morphologic damage to the kidney after drug
treatment: proximal tubule degradation, loss of brush border, tubular casts,
proximal tubule dilation, proximal tubule necrosis, presence of inflammatory cells,
and interstitial fibrosis. These measures were evaluated on a scale from 0 to 4,
which ranged from not present (0), mild (1), moderate (2), severe (3), and very
severe (4).
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Sirius Red/ Fast Green Staining
Kidney sections (5 μm thick) were rehydrated in Histoclear followed by an
ethanol gradient. Slides were then dipped in PBS with 0.1% Tween 20 and
incubated for 5 minutes. Slides were washed with distilled water twice for 5
minutes each and then incubated in 1.2% (w/v) saturated picric acid (#5860-32,
Ricca Chemicals) containing 0.1% sirius red/direct red 80 (#365548, Sigma) and
0.1% fast green FCF (#F7258, Sigma). Slides were then washed with 5% glacial
acetic water until the water ran clear. Tissue samples were then dehydrated and
ﬁxed using Permount (#17986-01, Electron Microscopy Sciences).
Statistical Analysis Data
Data are expressed as means ± SEM for all experiments. Multiple comparisons
of normally distributed continuous data were analyzed by two-way ANOVA and
group means were compared using Tukey post-tests. Nonparametric continuous
data were analyzed with a Kruskal-Wallis test followed by a Dunn’s multiple
comparison test. Nominal data from pathology scoring were analyzed by
individual Chi-squared tests. The criterion for statistical differences was p < 0.05
for all comparisons.
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RESULTS
nCDase knockout confers resistance to serum withdrawal in vitro. We had
previously shown that nCDase knockout conferred resistance to ER stress- and
nutrient deprivation- induced cell death.[69] These experiments were done with
pharmacological agents that blocked cellular metabolism and/or directly acted on
cellular organelles. To follow up these experiments, we also wanted to test this
idea in a more natural model of ischemic injury. We used mouse embryonic
fibroblasts (MEFs) grown from wild type and nCDase knockout C57BL/6 mice as
described previously.[69] These cells were cultured in media at varying
concentrations of fetal bovine serum (FBS) for 24, 48, and 72 hours. Cellular
viability was monitored via measuring relative cell numbers through Alamar Blue
fluorescence. We found that nCDase knockout cells had significantly higher
viability at 0.625% and 0% FBS at all timepoints compared to wild type controls.
Viability was also significantly higher at 1.25% FBS at 48 hours (Fig 1). These
data indicate that nCDase knockout provides protection from a serum withdrawal
model of nutrient depletion.
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Figure 1. Viability of nCDase knockout and wild type MEFs during FBS withdrawal.
Cells were plated at 2,000 cells per well in a 96-well plate on day 1. The next day cells
were washed with PBS then treated with the appropriate media. Viability was measured 24,
48, and 72 hours from treatment via alamar blue assay. * denotes significance of p<0.05.
WT indicates wild type MEFs, KO indicates nCDase knockout MEFs.
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nCDase knockout alters signaling pathways connected to autophagy and
cell survival. It had previously been shown that upregulation of autophagy was
the mechanism by which nCDase knockout provides protection from nutrient
stress.[69] We verified that the autophagic marker LC3B was upregulated basally
in nCDase KO cells as compared to WT cells as was previously reported by
Sundaram et. al. We wanted to also determine if pathways that regulate
autophagy are altered basally in cells deficient in nCDase. To this end, we
performed western blot analysis of protein kinase B (AKT) and glycogen
synthase kinase 3 beta (GSK3β) in MEF wild type and nCDase knockout cells.
Data revealed upregulation of phosphorylated AKT (p-AKT) as well as increased
phosphorylation of GSK3β (p-GSK3β) (Fig 2). The increase in p-AKT along with
p-GSK3β follows the reported regulation of GSK3β activity, as p-AKT
phosphorylates and inactivates GSK3β. GSK3β inactivation or inhibition has
been reported to upregulate pro-survival autophagy.[72, 73] It has also been
reported that inhibition of GSK3β can protect from necrotic and apoptotic cell
death by preventing mitochondrial permeability transition.[72] Although further
characterization is needed to suggest these pathways are essential for nCDase
knockout mediated protection from nutrient stress, literature suggests it could
play a role. These processes would also likely be protective in the high-dose
cisplatin model, as previous work has shown that autophagy plays a protective
role.[47]
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Figure 2. Upregulation of p-AKT and inhibition of GSK3β are induced by nCDase
knockout.
Wild type and nCDase knockout MEFs were cultured in DMEM containing 10% FBS.
Cells were pelleted and lysed with cell extraction buffer containing protease and
phosphatase inhibitors. 20 μg of protein were then taken for western blot analysis. WT
indicates wild type MEFs, KO indicates nCDase knockout MEFs.
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Pharmacological inhibition of nCDase induces signaling changes as seen
in genetically modified MEFs. In order to test whether signaling changes
observed in nCDase knockout MEFs were due to long term compensation or
acute inhibition of nCDase, we used two pharmacological inhibitors of nCDase in
wild type MEF cells in vitro. C6-urea ceramide (C6) is a widely used inhibitor of
nCDase but is known to have high levels of toxicity due to off target effects. We
also used a newly developed nCDase inhibitor from Ono Pharmaceutical
Company (ONO). We wanted to inhibit nCDase at a concentration that was not
lethal to cells yet still provided adequate enzymatic inhibition. Viability of MEF
wild type cells was assessed under treatment with a wide range of
concentrations of both ONO and C6 drug over a period of 72 hours. The ONO
drug was shown to be less toxic then C6 (Fig 3a and 3b). At 50 μM, ONO treated
wild type MEFs still displayed around 50% viability. At 50 μM, C6 killed all wild
type MEFs by 24 hours. We also observed that ONO showed some selectivity in
killing wild type MEFs more effectively than nCDase knockouts (Fig 3a and 3b).
This indicates ONO may be acting in a more targeted manner. We also tested
the activity of the drugs in vitro, using a TLC enzymatic activity assay with
recombinant nCDase (Fig 3c, Fig 3d). From these experiments, we identified a
smaller range of concentrations where nCDase inhibition was observed. Western
blot analysis of MEFs treated at these concentrations of inhibitor revealed that
pharmacologic inhibition of nCDase resulted in upregulation of p-AKT, p-GSK3β,
and LC3 as previously seen with genetic knockout of nCDase (Fig 4). This

42

suggests that these effects may be due to acute inhibition of nCDase activity and
not long-term compensation.
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Figure 3. Viability and nCDase enzymatic activity of wild type MEFs treated with
pharmacologic inhibitors of nCDase.
(A,B) Wild type MEFs were plated at 1,000 cells per well in a 96-well plate. Ono drug
(3a) or C6 (3b) concentrations were added the next day. Viability was monitored via
alamar blue assay over 72 hours. WT indicates wild type MEFs, KO indicates nCDase
knockout MEFs (C,D) nCDase inhibition was assessed using an in vitro, TLC activity
assay of wild type MEFs treated with inhibtiors. Inhibition of ceramide conversion to
sphingosine was observed under both Ono (3c) and C6 (3d) treatment.
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Figure 4. Acute inhibition of nCDase confers signaling changes as seen in
nCDase knockout MEFs.
Wild type and nCDase knockout MEFs were cultured for 24 hours in the presence of
either Ono or C6 drug. Cells were then harvested and lysed in cell extraction buffer
containing protease and phosphatase inhibitors. 20 μg of protein were then analyzed
for each condition via western blot. WT indicates wild type MEFs, KO indicates
nCDase knockout MEFs.
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Loss of nCDase confers resistance to AKI following high-dose cisplatin
treatment. Our in vitro results above and elsewhere[69] indicated that nCDase
knockout protects MEFs from ER stress and nutrient deprivation via upregulation
of autophagy. Upregulation of autophagy has been reported to be protective in
acute models of CDDP-KI.[70] In order to test the effects of nCDase on the
development of AKI following acute, high-dose cisplatin treatment, we utilized a
colony of C57BL/6 mice with a neo cassette inserted into the encoding gene of
nCDase. As a result, mice homozygous for this gene produce a nonfunctional
nCDase (nCDase -/-). We found that genetic inhibition of nCDase in vivo also
leads to an increase in the LC3B marker of autophagy in the kidney cortex (Fig
5). Following treatment with high dose cisplatin, nCDase -/- mice displayed
resistance to acute kidney injury development. Kidney function as measured by
BUN was significantly lower in nCDase -/- mice 72 hours post cisplatin treatment
(Fig 6a). Serum creatinine (SCr) and NGAL levels also appeared lower in
nCDase -/- mice compared to wild type although these results were not
significant (Fig 6b, Fig 6c). nCDase -/- mice had significantly lower levels of
tubular necrosis, cast formation, inflammatory cells, and loss of brush border as
determined by pathology. Tubular dilation and tubule degeneration was also
lower in nCDase -/- mice compared to wild type although these results were not
significant (Fig 7b-g). Inflammatory cytokine production following cisplatin
treatment was also assessed using qRT-PCR of kidney tissue. TNFα, IL6, MCP1, and CXCL1 levels were lower in nCDase -/- mice but were not statistically
different from wild type (Fig 8a-d).
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Figure 5. nCDase -/- mice display increased LC3 expression compared to wild
type.
Renal cortex and medulla from vehicle treated wild type and nCDase -/- mice were
harvested and prepped for western blot analysis. WT indicates wild type mice, KO
indicates nCDase -/- mice. Experiment done by Dr. Tess Dupre.
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Figure 6. Loss of nCDase attenuates AKI following high-dose cisplatin treatment.
C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg
cisplatin or normal saline. Mice were sacrificed 72 hours after cisplatin treatment and
kidney injury markers were assessed. (A,B) BUN and SCr were measured from serum
of cisplatin and vehicle treated wild type and nCDase -/- mice. (C) NGAL levels were
assessed from urine of cisplatin and vehicle treated wild type and nCDase -/- mice.
(D) Mouse body weight was measured each day following cisplatin treatment. *
signifies statistically different than vehicle treated WT mice. # signifies statistically
different than cisplatin treated WT mice. ^ signifies statistically different than vehicle
treated KO mice. Experiment was performed by Dr. Tess Dupre, data were
reanalyzed by Sophia Sears.
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Figure 7. Loss of nCDase protects from high-dose cisplatin-induced
deterioration in kidney pathology.
C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg
cisplatin or normal saline. Mice were sacrificed 72 hours after cisplatin treatment.
Renal histological changes were assessed on H&E and PAS stained sections 5
μm thick. (A) Representative images of renal histology at 200X magnification. (B)
Tubular necrosis, (C) loss of proximal tubule brush borders, (D) proximal tubule
cast formation, (E) inflammatory cells, (F) tubule degeneration, and (G) tubule
dilation were assessed as markers of histological changes. For figures (B-G),
scoring of the sections was performed in a blinded manner by renal pathologist
Dr. Megyesi using a scale of 0-4 (0=not present, 1=mild, 2=moderate, 3=severe,
and 4=very severe renal histological changes in the proximal tubules). WT
indicates wild type mice, KO indicates nCDase-/- mice. * signifies statistically
different than vehicle treated WT mice. # signifies statistically different than
cisplatin treated WT mice. ^ signifies statistically different than vehicle treated KO
mice. Experiment was performed by Dr. Tess Dupre, data were reanalyzed by
Sophia Sears.
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Figure 8. Loss of nCDase decreases mRNA expression of inflammatory
cytokines in the kidney following high-dose cisplatin treatment.
C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg cisplatin
or normal saline. Mice were sacrificed 72 hours after cisplatin treatment. Relative
expression of (A) TNFα, (B) IL6, (C) MCP-1, and (D) CXCL1 mRNA were measured via
qRT-PCR. WT indicates wild type mice, KO indicates nCDase-/- mice. * signifies
statistically different than vehicle treated WT mice. # signifies statistically different than
cisplatin treated WT mice. ^ signifies statistically different than vehicle treated KO mice.
Experiment done by Dr. Tess Dupre, data were reanalyzed by Sophia Sears.
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nCDase -/- mice have reduced apoptosis following high-dose cisplatin
treatment. It is well established that the acute, high-dose model of cisplatininduced kidney injury causes a high level of apoptosis. This high level of cell
death mediates the pathological changes that manifest as acute kidney injury.
We hypothesized that nCDase -/- may mediate protection from high-dose
cisplatin by preventing cell death, as previously seen in our in vitro models of cell
stress. In order to assess the level of apoptosis occurring in vivo, we performed a
western blot of cleaved caspase 3. Following cisplatin treatment nCDase -/- mice
had no detectable expression of cleaved caspase 3 (CC3) while wild type mice
showed increased levels of CC3 as compared to vehicle treated mice (Fig 9a).
We also performed TUNEL staining on wild type and nCDase -/- mice following
cisplatin treatment. We found nCDase -/- mice treated with cisplatin had
significantly less TUNEL-positive apoptotic cells then wild type treated mice (Fig
9b). These data indicate that nCDase -/- blocks induction of apoptotic cell death
typically triggered by high-dose cisplatin.
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Figure 9. Loss of nCDase attenuates high-dose cisplatin-induced apoptosis.
C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg cisplatin or
normal saline. Mice were sacrificed 72 hours after cisplatin treatment. (A) Western blot
analysis was performed to assess relative protein levels of cleaved caspase 3 in the renal
cortex of mice. (B-C) TUNEL assays were performed on paraffin embedded kidney sections
as an index of apoptosis. (B) Representative photomicrographs of TUNEL assays (final
magnification 200X). (C) TUNEL quantification. WT indicates wild type mice, KO indicates
nCDase-/- mice. * signifies statistically different than vehicle treated WT mice. # signifies
statistically different than cisplatin treated WT mice. ^ signifies statistically different than
vehicle treated KO mice. Experiment done by Dr. Tess Dupre.
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nCDase -/- mice have reduced levels of ER stress following high-dose
cisplatin treatment. Cisplatin has been shown to induce ER stress as a
mechanism of cell toxicity.[50] In order to assess how nCDase -/- would affect
induction of ER stress we performed western blot analysis on wild type and
nCDase -/- mice treated with cisplatin or vehicle. We found the nCDase -/- mice
treated with cisplatin had reduced levels of ER stress markers p-JNK, CHOP,
and p-eIF2α compared to wildtype mice treated with cisplatin (Fig 10). These
data indicate that nCDase -/- blocks high-dose cisplatin-induced ER stress.
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Figure 10. Loss of nCDase attenuates high-dose cisplatin-induced ER stress.
C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 20 mg/kg
cisplatin or normal saline. Mice were sacrificed 72 hours after cisplatin treatment.
Western blot analysis was performed to assess relative protein levels of markers
of ER stress in the renal cortex of mice. WT indicates wild type mice, KO
indicates nCDase-/- mice. Experiment done by Dr. Tess Dupre.
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Repeated low-dose cisplatin (RLDC) induces signaling pathways similar to
nCDase -/- triggered pathways. As more information is being revealed about
the interconnectedness of AKI and CKD, it is becoming increasingly important to
test prospective nephroprotective agents in models of both types of injury. With
the development of our RLDC model, we had the capability to test nCDase as a
target for cisplatin-induced renal fibrosis and CKD. As the pathology associated
with our RLDC model is somewhat different than what is seen in the high-dose
model, we were unsure if nCDase -/- would mediate protection. However, upon
analysis of wild type mice treated with RLDC we found signaling pathways were
altered in a manner consistent with nCDase -/- mediated signaling changes in
vitro. p-AKT, p-GSK3β, and LC3 expression was upregulated in wild type mice
following RLDC (Fig 11). Therefore, we hypothesized that nCDase -/- may confer
resistance to RLDC induced kidney injury.
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Figure 11. RLDC treatment of C57BL/6 mice induces changes in protein
expression similar to those triggered by nCDase inhibition in vitro.
Wild type C57BL/6 mice were injected (i.p.) with either 9 mg/kg cisplatin or normal
saline once a week for four weeks. Mice were sacrificed 72 hours following the final
dose. Expression of the indicated proteins was evaluated from renal cortex using
western blot.
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nCDase inhibition does not protect from RLDC induced kidney injury.
C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with 9
mg/kg cisplatin or saline once a week for four weeks. 500 μl saline was injected
(subQ) 1 day before dose 3, two days after dose 3, and 1 day before dose 4.
Mice were sacrificed 72 hours following the last dose. Kidney function was
evaluated by BUN, NGAL, and Kim-1 levels. Following RLDC there appeared to
be no difference in BUN, NGAL, or Kim-1 levels between all cisplatin treated
groups. All cisplatin treated groups had significantly elevated BUN, NGAL, and
Kim-1 levels compared to vehicle treated controls (Fig 12a-c). Throughout RLDC,
mouse body weights were monitored. Saline was administered to ensure weight
loss did not fall below 25%. All cisplatin treated mice appeared to have equal
amounts of weight loss throughout RLDC regardless of their genotype (Fig 12d).
Upon pathology assessment, nCDase -/-, nCDase -/+, and wild type mice
appeared to have similar levels of damage in the measures assessed (Fig 13).
Cisplatin treatment unexpectedly caused significant increases in tubular necrosis
and tubular regeneration not seen in FVB mice under RLDC treatment.[57]
Inflammatory cytokine expression following RLDC also indicated nCDase
inhibition did not provide a protective effect. TNFα, IL6, MCP-1, and CXCL1
mRNA expression were similar between all cisplatin treated groups (Fig 14a-d).
We also evaluated iNOS and Arg-1 mRNA expression to assess the level of M1
and M2 macrophages present. Genotype did not appear to influence iNOS or
Arg-1 levels. Cisplatin treatment caused a significant decrease in iNOS
expression and increase in Arg-1 expression as previously characterized (Fig
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14e-f). These data indicate that nCDase -/- does not prevent renal function loss
or injury development following RLDC.
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Figure 12. nCDase -/- does not prevent RLDC induced kidney injury.
C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with either 9 mg/kg
cisplatin or normal saline once a week for four weeks. 500 μl saline was injected (subQ) 1
day before dose 3, 2 days after dose 3, and 1 day before dose 4. Mice were sacrificed 72
hours following the final dose. (A) BUN levels were determined from serum. (B) NGAL
levels were measured from the urine. (C) Kim-1 mRNA expression was measured via qRTPCR analysis of renal cortex. (D) Percent body weight change was tracked throughout
RLDC as a measure of overt toxicity. WT indicates wild type mice, HET indicates nCDase /+ mice, KO indicates nCDase -/- mice. * signifies statistically different than vehicle treated
WT mice. + signifies statistically different than vehicle treated HET mice. ^ signifies
statistically different than vehicle treated KO mice.
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Figure 13. Loss of nCDase does not protect from RLDC induced renal pathology.
C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with either 9
mg/kg cisplatin or normal saline once a week for four weeks. 500 μl saline was
injected (subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4.
Mice were sacrificed 72 hours following the final dose. Renal histological changes
were assessed on H&E and PAS stained sections 5μm thick. (A) Tubular necrosis, (B)
loss of proximal tubule brush borders, (C) proximal tubule cast formation, (D) tubule
degeneration, (E) inflammatory cells, (F) widening of interstitium, (G) tubule dilation,
and (H) tubular regeneration were assessed as markers of histological changes.
Scoring of the sections was performed in a blinded manner by renal pathologist Dr.
Megyesi using a scale of 0-4 (0=not present, 1=mild, 2=moderate, 3=severe, and
4=very severe renal histological changes in the proximal tubules). WT indicates wild
type mice, HET indicates nCDase -/+ mice, KO indicates nCDase -/- mice. * signifies
statistically different than vehicle treated WT mice. + signifies statistically different than
vehicle treated HET mice. ^ signifies statistically different than vehicle treated KO
mice.
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Figure 14. nCDase inhibition does not alter inflammatory cytokine production or
macrophage involvement in RLDC.
C57BL/6 wild type, nCDase -/-, and nCDase -/+ mice were injected (i.p.) with either 9
mg/kg cisplatin or normal saline once a week for four weeks. 500 μl saline was
injected (subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4.
Mice were sacrificed 72 hours following the final dose. Relative mRNA expression of
(A) TNFα, (B) IL6, (C) MCP-1, (D) CXCL1, (E) iNOS, and (F) Arg-1 were measured via
real-time qRT-PCR. WT indicates wild type mice, HET indicates nCDase -/+ mice, KO
indicates nCDase-/- mice. * signifies statistically different than vehicle treated WT mice.
+ signifies statistically different than vehicle treated HET mice. ^ signifies statistically
different than vehicle treated KO mice.
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nCDase inhibition does not protect from development of fibrosis following
RLDC. Previously, it had been shown that RLDC leads to collagen deposition
and development of interstitial fibrosis.[57] We evaluated the development of
fibrosis in wild type and nCDase -/- mice following RLDC using several methods.
We detected levels of fibronectin expressed in the renal cortex using western
blot. Our results suggest fibronectin expression is induced in both wild type and
nCDase -/- mice in a similar fashion (Fig 15a). Sirius red fast green staining was
also done to evaluate collagen deposition. In this stain, all collagen is dyed red
while non-collagenous proteins are dyed green. Following RLDC, we saw similar
amounts of collagen deposition in both wild type and nCDase -/- treated mice
(Fig 15b). Fibrosis was also assessed by the pathological measure of widening of
the interstitium. There was no difference in this measure among nCDase -/-,
nCDase -/+, and wild type mice treated with cisplatin (Fig 13f). Interestingly,
pathological assessment revealed our C57BL/6 mice may develop lower levels of
fibrosis than what we’ve observed in FVB mice previously.[57] These data
suggest nCDase does not play a role in development of fibrosis following RLDC.
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Figure 15. nCDase inhibition does not alter fibronectin expression or collagen
deposition following RLDC.
C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 9 mg/kg
cisplatin or normal saline once a week for four weeks. 500 μl saline was injected
(subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4. Mice were
sacrificed 72 hours following the final dose. (A) Protein expression of fibronectin in
the renal cortex was evaluated via western blot. (B) Sirius red fast green staining was
performed on nCDase -/- and wild type mice. WT indicates wild type mice, KO
indicates nCDase-/- mice.
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nCDase inhibition no longer attenuates cisplatin-induced ER stress. Having
previously observed that nCDase -/- mice were resistant to ER stress in the highdose cisplatin model, we wanted to evaluate if this protection persisted in the
RLDC model. We evaluated protein expression of ER stress markers CHOP,
JNK, and NF-κB. Our data indicate that ER stress is induced in the RLDC model
and nCDase inhibition does not block this induction (Fig 16). This suggests that
RLDC employs different mechanisms of activating ER stress than what has
previously been observed in the high-dose cisplatin model.
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Figure 16. nCDase -/- mice are not protected from ER stress in RLDC.
C57BL/6 wild type and nCDase -/- mice were injected (i.p.) with either 9 mg/kg
cisplatin or normal saline once a week for four weeks. 500 μl saline was injected
(subQ) 1 day before dose 3, 2 days after dose 3, and 1 day before dose 4. Mice were
sacrificed 72 hours following the final dose. (A) Protein expression of the indicated
ER stress markers from the renal cortex was evaluated via western blot. WT indicates
wild type mice, KO indicates nCDase-/- mice.
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DISCUSSION
This study evaluates the role of neutral ceramidase (nCDase) in an in vitro
system as well as in vivo in two different models of CDDP-KI. In vitro, nCDase
knockout in mouse embryonic fibroblasts (MEFs) promoted increased autophagy
and resistance to nutrient deprivation induced cell death. Our results in vivo
indicate that nCDase knockout offers protection from high-dose cisplatin induced
acute kidney injury (AKI) by preventing ER stress and apoptotic cell death. In the
repeated low dose cisplatin (RLDC) model, nCDase knockout does not provide
protection from kidney injury and development of fibrosis. nCDase knockout also
does not block ER stress induction in the RLDC model.
These results indicate the importance of testing potential nephroprotective
agents in both models of AKI and chronic kidney disease (CKD). It has been
speculated that the RLDC model of injury employs the same mechanisms as the
standard high-dose model. Here, we demonstrate that that is not likely the case.
If the same mechanism of nephrotoxicity was produced in both models, nCDase
knockout would have been protective in RLDC. The lack of protection in this
model can give us clues into what mechanisms may be unique to RLDC induced
nephrotoxicity.
In the high-dose model, AKI development is dependent on cell death. We
have established nCDase knockout blocks cell death in both in vitro models of
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stress and in vivo in the high-dose model of cisplatin injury. Therefore, nCDase
knockout provides protection from high-dose cisplatin. Previously, the RLDC
model has not been shown to induce large levels of apoptosis or necrosis.[58] In
this study, apoptosis was not measured but high levels of tubular necrosis were
observed by pathology. We do not believe the driving pathology in RLDC induced
fibrosis is cell death, but it could be a side effect of CKD development. In the
high-dose model, cell death is the cause of AKI development. In the RLDC
model, we believe cell death may be an effect of CKD development. Other
studies have demonstrated how repeated sublethal injuries can lead to different
renal outcomes than what is observed in acute models of kidney injury.
Grgic et. al. examined how multiple sublethal insults to tubule epithelial
cells promotes interstitial fibrosis and other CKD pathologies. They utilized renal
epithelial cells expressing a diphtheria toxin receptor. Administration of diphtheria
toxin resulted in specific renal epithelial cell death. Using this model, they
demonstrated that a large, acute insult to tubule cells led to an inflammatory
response and tubule cell proliferation allowing for complete recovery. With
repeated, lower levels of injury they observed that the kidney underwent
maladaptive repair followed by development of fibrosis and glomerulosclerosis.
They speculated that repeated injury caused tubule cells to lose their replicative
capacity and resulted in either senescence or a prolonged dedifferentiated
state.[74] Cell cycle G2/M arrest has been identified as a contributor to fibrotic
outcomes in renal models of injury. G2/M cell cycle arrest is also associated with
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high levels of JNK signaling and secretion of profibrotic cytokines such as
TGFβ.[21]
Our current and past studies indicate that RLDC may also be causing cell
cycle arrest and senescence. We see increased p-JNK protein expression (Fig
16)[58] and TGFβ mRNA expression [58] with RLDC. We have also observed in
this study (data not shown) and in the past [58] that RLDC causes increased
mRNA expression of cyclin dependent kinase inhibitor 2a (CDKN2A), a known
marker of cellular senescence. Therefore, we hypothesize that RLDC induced
fibrosis is being driven by G2/M cell cycle arrest of tubule cells as they attempt to
proliferate and repair renal damage.
More studies are needed to verify whether tubule cells in the RLDC model
are undergoing cellular senescence. We also need to examine levels of cell
death at earlier timepoints in RLDC. These studies will help determine when
senescence occurs and what cells are responsible. It could be that initially injured
tubule cells remain and senesce, or there could be an initial cell death response
to injury followed by uninjured tubule cell dedifferentiation and replication that is
impaired upon repeated insults.
Another possibility for the differences in nCDase knockout outcomes in
high-dose cisplatin and RLDC could be due to varied roles of autophagy in acute
and chronic kidney injury. In the acute model of cisplatin injury, autophagy has
been shown to be protective. Takahashi et. al. demonstrated that high-dose
cisplatin treatment led to upregulation of autophagy in the kidney. They then
treated mice with proximal tubule specific autophagy deficiency and found that
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they were more sensitive to injury. They also found that autophagy deficient mice
had increased DNA damage, p53 activation, protein aggregation, and apoptosis
following cisplatin treatment.[70] In this study, it is clear that autophagy protects
against cellular damage induced by high dose cisplatin. Therefore, nCDase
knockout would provide protection via upregulation of autophagy.
In chronic models of kidney injury, the role of autophagy is less well
defined. Nam et. al. made use of mice with distal tubule specific conditional
knockout of autophagy related 7 (Atg7). These mice had deficient autophagy in
the renal distal tubule cells compared to controls. Following unilateral ureteral
obstruction, these mice had increased levels of renal fibrosis. Distal tubule
autophagy deficiency was also associated with increased TGFβ expression.[75]
In contrast to this study, Livingston et. al. used mice with a proximal tubule
specific conditional knockout of Atg7. They found that mice deficient in proximal
tubule autophagy had decreased levels of renal fibrosis following unilateral
ureteral obstruction. They also saw decreased levels of renal fibrosis in mice
treated with pharmalogical inhibitors of autophagy, chloroquine and 3methyladenine, prior to injury. Interestingly, this group saw no effect on TGFβ
expression in autophagy impaired groups following injury.[76] These studies and
others indicate that the role of autophagy in renal fibrosis may be context and
cell-type dependent.[52]
There are several experiments we could do in the future to determine the
role of autophagy in our RLDC model. First, we must examine how RLDC alters
autophagy. We could treat a GFP-LC3 mouse with RLDC and observe
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autophagic flux at different time points. Once we determine how RLDC influences
autophagy, we could make use of both pharmalogical inhibitors and conditional
knockout mice to inhibit autophagy at different points of RLDC. Following
inhibition we could examine outcomes of renal fibrosis and myofibroblast
production to determine what role autophagy may be playing in disease
progression.
There is also a need to evaluate ER stress induction in both the high-dose
and RLDC models. ER stress describes a disruption in ER homeostasis involving
accumulation of misfolded proteins within the ER. This results in activation of the
unfolded protein response (UPR) or cell death. The UPR is activated in an
attempt to restore physiological function to the ER. However, long term activation
of UPR can lead to permanent functional changes.[77]
In this study, we demonstrated that nCDase knockout was sufficient to
block ER stress induction in the high-dose model. In the RLDC model, nCDase
knockout no longer blocked this induction. This suggests that there are different
activators of ER stress in these models. Induction of ER stress in the RLDC
model also appears to be occurring independently of cell death. This suggests
that there is an adaptive response to ER stress in the RLDC model.
ER stress involves several complex signaling cascades. There are three
main proteins thought of as activators of ER stress: pancreatic endoplasmic
reticulum kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating
transcription factor 6 (ATF6). Each of these proteins trigger pathways involved in
regulation of UPR and apoptotic responses.[77] We hypothesize that the extent
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of activation in each of these arms may differ in high-dose cisplatin model and
the RLDC model. This may account for the differential ER stress activation in
nCDase knockout mice. It may also account for the difference in ER stress
outcomes.[78] Future studies aimed at understanding the different drivers of ER
stress in the two models are needed.
Once activated, ER stress can lead to outcomes ranging from apoptosis to
adaptation. Responses to ER stress depend on both the amount of cellular
damage done as well as the length of time the insult persists. With acute insults,
cells only need to withstand stress for a short period of time. Recovery depends
on how quickly the cell can mount the UPR and clear accumulated unfolded
proteins. Following clearance cellular function can return to normal. With chronic
stress, the cell must undergo a functional change that is more permanent. This
functional change and prolonged UPR allows cells to adapt to the chronic stress
and escape cell death.[78]
We hypothesize that in RLDC, tubule cells undergo functional changes in
order to adapt to chronic ER stress. This adaptive response likely involves
transcriptional upregulation of genes involved in protein folding and processing
as well as alteration of metabolic function.[78] Chronic ER stress has previously
been linked to CKD progression.[79] One study demonstrated that inhibition of
ER stress following renal ischemia-reperfusion prevented development of
fibrosis.[80] Future studies are needed utilizing the RLDC model in which ER
stress is inhibited to determine its role in fibrosis development.
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Literature also reports a close relationship between ER stress and
autophagy. There is evidence to support ER stress induction and inhibition of
autophagy.[51] The UPR has been shown to induce autophagy through IRE1α
and PERK signaling. This induction is thought to act as a pro-survival response,
helping clear damaged cellular debris and restore ER homeostasis. However, it
has also been demonstrated that ER stress induced autophagy can mediate cell
death through caspase 8 activation.[77] In the high-dose cisplatin model, it is
possible that the upregulation of autophagy in nCDase knockout mice facilitates
resistance to ER stress induction. In the RLDC it is less clear how ER stress and
autophagy are being regulated. Future studies aimed at understanding the role of
autophagy in the RLDC model and the relationship between autophagy and ER
stress are needed.
This study reveals how nephroprotective agents can have differential
success in the high-dose cisplatin model and the RLDC model due to the
inherent biological differences in these two models in the induction of cell
death/senescence, ER stress induction and response, and autophagy.
Evaluating the success of different therapeutic strategies in these models may
help shed light on the different nephrotoxic mechanisms employed by high-dose
cisplatin and RLDC treatment.
It is important to take into account both acute and chronic renal injury
when developing nephroprotective agents. Patients exhibit a wide range of
response to cisplatin in the clinic. Some develop AKI after a single low dose while
others may receive multiple doses without displaying signs of clinical AKI.
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Developing an understanding of the biological processes occurring in both the
high-dose cisplatin and RLDC models will help us understand the pathological
processes occurring in all categories of patients. This will lead to better treatment
of AKI and prevention of CKD.
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SUMMARY
Cisplatin is a commonly used chemotherapeutic agent with dose limiting
nephrotoxicity. 10-20% of cancer patients will receive cisplatin as part of their
treatment regimen. 30% of these patients will develop acute kidney injury (AKI),
or a rapid decline in renal function. Even patients that do not develop AKI by
clinical standards are still at risk for long term declines in renal function.
Development of kidney injury greatly increases risk of mortality and development
of chronic kidney disease (CKD).
AKI is associated with high levels of tubule cell death, robust inflammation,
and vascular damage. This type of injury has been experimentally modeled by
giving mice a single, high dose of cisplatin. Mice do not survive longer then 3-4
days after treatment. CKD is associated with interstitial fibrosis, chronic
inflammation, and vascular rarefaction. Recent studies have brought to light the
interconnectedness of AKI and CKD through processes of maladaptive repair. In
order to develop better nephroprotective agents we must use models that allow
for study of this progression following cisplatin treatment. Our repeated low dose
cisplatin (RLDC) model utilizes 4 weekly low doses of cisplatin that enable mice
to survive up to 6 months after treatment. This allows for evaluation of long-term
progression to CKD.
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We used both the high-dose cisplatin and RLDC models to assess the
effects of neutral ceramidase (nCDase) on renal injury. We found that nCDase
knockout mice were protected from AKI development in the high-dose cisplatin
model. In contrast, nCDase knockout mice were not protected from development
of renal fibrosis in the RLDC model. These experiments demonstrate that the
high-dose cisplatin and RLDC models utilize different mechanisms of
nephrotoxicity. While the high-dose cisplatin model has been well characterized,
less is known about the RLDC model. Future studies will be aimed at further
characterizing cell death, cell cycle arrest, autophagy, and ER stress in the
RLDC model.
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